Abeona Therapeutics reported a net loss of $84.9 million for the full year 2021. The company is focusing on EB-101 and expects topline results in Q3 2022. They also plan to reduce operating expenses and extend cash runway to mid-2023.
EB-101 pivotal phase 3 VIITALâ„¢ study in RDEB achieved target enrollment; top-line data expected in third quarter of 2022.
The company gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans.
The company will pursue a strategic partner to take over development activities for ABO-102 for MPS IIIA, while discontinuing development of ABO-101 for MPS IIIB.
The company plans to reduce operating expenses and extend cash runway to mid-2023.
Abeona Therapeutics is focused on developing novel cell and gene therapies for patients with rare diseases with no approved treatment options and plans to extend their cash runway.
Analyze how earnings announcements historically affect stock price performance